Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis: an observational study.
Aged
Cross-Sectional Studies
Echocardiography
Female
Follow-Up Studies
Heart Failure
/ complications
Heart Valve Diseases
/ complications
Humans
Kaplan-Meier Estimate
Kidney Failure, Chronic
/ complications
Male
Middle Aged
Prognosis
Proportional Hazards Models
Renal Dialysis
Stroke Volume
Ventricular Dysfunction, Left
/ complications
Cardiovascular
Dialysis
Echocardiography
End-stage renal failure
Heart failure
Left ventricular systolic dysfunction
Mortality
Outcome
Survival
Valve disease
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
25 09 2020
25 09 2020
Historique:
received:
20
04
2020
accepted:
18
09
2020
entrez:
26
9
2020
pubmed:
27
9
2020
medline:
12
10
2021
Statut:
epublish
Résumé
Cardiovascular disease is the most common cause of death in patients with end-stage kidney disease on haemodialysis. The potential clinical consequence of systematic echocardiographic assessment is however not clear. In an unselected, contemporary population of patients on maintenance haemodialysis we aimed to assess: the prevalence of structural and functional heart disease, the potential therapeutic consequences of echocardiographic screening and whether left-sided heart disease is associated with prognosis. Adult chronic haemodialysis patients in two large dialysis centres had transthoracic echocardiography performed prior to dialysis and were followed prospectively. Significant left-sided heart disease was defined as moderate or severe left-sided valve disease or left ventricular ejection fraction (LVEF) ≤40%. Among the 247 included patients (mean 66 years of age [95%CI 64-67], 68% male), 54 (22%) had significant left-sided heart disease. An LVEF ≤40% was observed in 31 patients (13%) and severe or moderate valve disease in 27 (11%) patients. The findings were not previously recognized in more than half of the patients (56%) prior to the study. Diagnosis had a potential impact on management in 31 (13%) patients including for 18 (7%) who would benefit from initiation of evidence-based heart failure therapy. After 2.8 years of follow-up, all-cause mortality among patients with and without left-sided heart disease was 52 and 32% respectively (hazard ratio [HR] 1.95 (95%CI 1.25-3.06). A multivariable adjusted Cox proportional hazard analysis showed that left-sided heart disease was an independent predictor of mortality with a HR of 1.60 (95%CI 1.01-2.55) along with age (HR per year 1.05 [95%CI 1.03-1.07]). Left ventricular systolic dysfunction and moderate to severe valve disease are common and often unrecognized in patients with end-stage kidney failure on haemodialysis and are associated with a higher risk of death. For more than 10% of the included patients, systematic echocardiographic assessment had a potential clinical consequence.
Sections du résumé
BACKGROUND
Cardiovascular disease is the most common cause of death in patients with end-stage kidney disease on haemodialysis. The potential clinical consequence of systematic echocardiographic assessment is however not clear. In an unselected, contemporary population of patients on maintenance haemodialysis we aimed to assess: the prevalence of structural and functional heart disease, the potential therapeutic consequences of echocardiographic screening and whether left-sided heart disease is associated with prognosis.
METHODS
Adult chronic haemodialysis patients in two large dialysis centres had transthoracic echocardiography performed prior to dialysis and were followed prospectively. Significant left-sided heart disease was defined as moderate or severe left-sided valve disease or left ventricular ejection fraction (LVEF) ≤40%.
RESULTS
Among the 247 included patients (mean 66 years of age [95%CI 64-67], 68% male), 54 (22%) had significant left-sided heart disease. An LVEF ≤40% was observed in 31 patients (13%) and severe or moderate valve disease in 27 (11%) patients. The findings were not previously recognized in more than half of the patients (56%) prior to the study. Diagnosis had a potential impact on management in 31 (13%) patients including for 18 (7%) who would benefit from initiation of evidence-based heart failure therapy. After 2.8 years of follow-up, all-cause mortality among patients with and without left-sided heart disease was 52 and 32% respectively (hazard ratio [HR] 1.95 (95%CI 1.25-3.06). A multivariable adjusted Cox proportional hazard analysis showed that left-sided heart disease was an independent predictor of mortality with a HR of 1.60 (95%CI 1.01-2.55) along with age (HR per year 1.05 [95%CI 1.03-1.07]).
CONCLUSION
Left ventricular systolic dysfunction and moderate to severe valve disease are common and often unrecognized in patients with end-stage kidney failure on haemodialysis and are associated with a higher risk of death. For more than 10% of the included patients, systematic echocardiographic assessment had a potential clinical consequence.
Identifiants
pubmed: 32977752
doi: 10.1186/s12882-020-02074-3
pii: 10.1186/s12882-020-02074-3
pmc: PMC7519512
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
413Références
J Am Soc Nephrol. 2014 May;25(5):1094-102
pubmed: 24335969
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Am J Kidney Dis. 2011 Jul;58(1):64-72
pubmed: 21458896
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Eur Heart J. 2012 Oct;33(19):2451-96
pubmed: 22922415
J Am Soc Nephrol. 2004 Apr;15(4):1029-37
pubmed: 15034106
Eur J Heart Fail. 2001 Aug;3(4):469-79
pubmed: 11511434
Am J Cardiol. 2017 May 1;119(9):1438-1442
pubmed: 28325569
Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1602-8
pubmed: 26138259
Int J Cardiovasc Imaging. 2019 Sep;35(9):1673-1681
pubmed: 31093896
JAMA. 2009 Oct 28;302(16):1782-9
pubmed: 19861670
Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153
pubmed: 15806502
Kidney Int. 2011 Sep;80(6):572-86
pubmed: 21750584
J Am Heart Assoc. 2017 Oct 11;6(10):
pubmed: 29021274
Blood Purif. 1996;14(4):321-6
pubmed: 8873958
Eur J Cardiothorac Surg. 2012 Oct;42(4):S1-44
pubmed: 22922698
Eur J Echocardiogr. 2009 Jan;10(1):1-25
pubmed: 19065003
J Am Coll Cardiol. 2003 May 7;41(9):1438-44
pubmed: 12742278
Kidney Int. 2006 Oct;70(7):1318-24
pubmed: 16871247
Clin J Am Soc Nephrol. 2012 Oct;7(10):1615-23
pubmed: 22822014
Acta Cardiol. 2013 Feb;68(1):51-7
pubmed: 23457910
Nephron. 1988;50(2):121-8
pubmed: 3065660
J Am Coll Cardiol. 2003 Jul 16;42(2):201-8
pubmed: 12875751
J Cardiol. 2015 May;65(5):353-9
pubmed: 25890579
Am J Kidney Dis. 2018 Sep;72(3):390-399
pubmed: 29784617
Am J Nephrol. 1990;10(3):213-21
pubmed: 2143353
J Am Coll Cardiol. 2010 Nov 16;56(21):1701-8
pubmed: 21070920
Am J Kidney Dis. 2002 Nov;40(5):1023-9
pubmed: 12407648
Clin J Am Soc Nephrol. 2010 Oct;5(10):1793-8
pubmed: 20595691
J Am Coll Cardiol. 2014 Feb 18;63(6):528-36
pubmed: 24184249
Clin J Am Soc Nephrol. 2013 Mar;8(3):355-62
pubmed: 23411431
Circulation. 2004 Dec 14;110(24):3667-73
pubmed: 15569840
J Renin Angiotensin Aldosterone Syst. 2002 Sep;3(3):188-91
pubmed: 12563570
JACC Heart Fail. 2016 Aug;4(8):649-61
pubmed: 27179827
Surg Neurol. 1995 Jan;43(1):52-7; discussion 57-8
pubmed: 7701424